Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2
Author: admintech | Filed under: World
This entry was posted
on Monday, December 14th, 2020 at 7:06 am and is filed under World.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.